US › Healthcare

Intensity Therapeutics, Inc. Common stock (INTS)

US · Healthcare · Biotechnology

$3.88+1.84%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.0M

EPS

$-1.11

EPS estimate

$-0.81

EPS came in at -1.11 against a street estimate of -0.81 — a miss of 37.0%.

Key statistics

Market cap

$13.0M

Forward P/E

0.0

P/B

1.44

Book value

$3.13

EPS (TTM)

$-2.00

52-week high

$43.50

52-week low

$3.51

50-day MA

$4.39

200-day MA

$6.44

Beta

3.03

Analyst view

Analysts rate Intensity Therapeutics, Inc. Common stock a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $19.33.

Shareholding

Insiders

3.77%

Institutions

36.57%

Largest institutional holders

Fund	Stake
KMT WEALTH MANAGEMENT, LLC	15.21%
Sentinus, LLC	0.82%
Geode Capital Management, LLC	0.80%
NANO CAP NEW MILLENNIUM GROWTH FUND L P	0.77%
Vanguard Capital Management, LLC	0.52%
Mesirow Fin Investmt Mgmt Intl Equity	0.43%
Vanguard Fiduciary Trust Co	0.28%
Goss Wealth Management LLC	0.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Intensity Therapeutics, Inc. Common stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.